Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
| Horizon | Bear case (−1σ) | Base case | Bull case (+1σ) |
|---|---|---|---|
| 1 Month | $3.50 (-35.1%) | $5.39 | $8.31 (+54.2%) |
| 3 Months | $2.55 (-52.8%) | $5.39 | $11.41 (+111.7%) |
| 6 Months | $1.87 (-65.4%) | $5.39 | $15.57 (+188.8%) |
| 12 Months | $1.20 (-77.7%) | $5.39 | $24.16 (+348.2%) |